Men With Breast Cancer Have Better Disease-Specific Survival Than Women

El‐Tamer, Mahmoud; Komenaka, Ian K.; Troxel, Andrea B.; Li, Huiling; Joseph, Kathie‐Ann; Ditkoff, Beth-Ann; Schnabel, Freya; Kinne, David W.

doi:10.1001/archsurg.139.10.1079

Cited by 59 publications

(59 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, when matched for stage, age and hormone receptor status, male and female breast cancer patients show the same over-all survival pattern [16]. Stage, nodal status (positivity and number of involved nodes), size and hormone receptor status are considered as important prognostic factors [12].…”

Section: Resultsmentioning

confidence: 99%

Male Breast Cancer: A Clinicopathologic Study of 42 Patients in Eastern India

Shah

Bhattacharyya

Gupta

et al. 2012

Indian J Surg Oncol

View full text Add to dashboard Cite

Retrospective review of presentation, treatment and outcome of male breast cancer in a tertiary cancer centre in eastern India. Data of 42 male breast cancer (MBC) patients, who presented between April, 2001 and March, 2008 were collected from institute records with respect to epidemiological characteristics, clinical and pathological parameters, treatment pattern and outcome. This series includes 42 patients with mean age of 56 years (range 31-78 years). MBC represented 1.1 % of all breast cancer. History of lump in the breast with duration ranging from 1 month to 4 years was the most common clinical presentation (80.95 %). Histopathology found infiltrating ductal carcinoma in 35 (83.33 %), followed by papillary carcinoma in 3 (7.14 %), undifferentiated carcinoma in 2 (4.76 %), mucinous carcinoma in 1 (2.38 %) and myxofibrosarcoma in 1 (2.38 %) patient. Hormone receptor (HR) study was performed on 29 patients. Twenty six (89.7 %) patients were hormone receptor positive in that 8 (27.6 %) were ER positive and 18 (62.1 %) were ER and PR positive. 3 (10.3 %) were hormone receptor negative.Axillary lymph node dissection was performed on 30 patients. Of those, 60 % were found to be positive (pN+) and 40 % were negative (pN-). Of the patients with invasive carcinoma 2.86 % were pathologic stage I, 37.14 % stage II, 42.86 % stage III and 17.14 % stage IV. Of the 35 treated patients, total 30 (85.71 %) patients underwent surgery. The surgery consisted of a modified radical mastectomy (MRM) 24 (80 %), radical mastectomy according to Halsted (RM) 6 (20 %). Adjuvant therapy i.e. Chemotherapy and Radiotherapy was administered to the patient based upon their stage. The standard treatment for all HR positive patients was administration of tamoxifen. Based upon the follow-up information (ranging from 17 month to 136 months), 4 (14.28 %) patients developed local recurrence over 4 to 26 months (mean17.5 months) and 5 patients developed distant metastasis over 24 to132 months (mean 78 months). Disease specific survival varied from 4 months to 132 months, with a mean of 56.75 months. Thirteen out of 28 evaluable patients (46.43 %) were disease free at 5 years. Male Breast cancer is a rare disease often ignored in the community, because of which it is seeks medical attention at advanced stage. Majority of MBC are found to be HR positive, hence hormonal therapy should to be strongly considered and multicentric prospective studies are needed to improve outcome.

show abstract

Section: Resultsmentioning

confidence: 99%

Male Breast Cancer: A Clinicopathologic Study of 42 Patients in Eastern India

Shah

Bhattacharyya

Gupta

et al. 2012

Indian J Surg Oncol

View full text Add to dashboard Cite

show abstract

“…Sabe-se que o tempo ideal de uso do tamoxifeno é de, no mínimo, cinco anos, sendo esse o período que deve ser utilizado para obtenção do seu melhor efeito 4,8 . É importante ressaltar que a terapia hormonal provavelmente deva ser indicada apenas em tumores positivos para receptores hormonais 14,26 . Os estudos sobre o tratamento adjuvante, incluindo os inibidores da aromatase (anastrazol e letrozol), ainda são insuficientes.…”

Section: Tratamentounclassified

“…O comprometimento dos linfonodos axilares é um fator prognóstico negativo e homens com linfonodos positivos têm risco de morte 50% maior, em relação aos casos com linfonodos negativos 4,27 . A ideia de que o câncer de mama masculino tem pior prognóstico do que o feminino perdurou por longos períodos na literatura 26 . Contudo, com a continuidade dos estudos, demonstrou-se que quando homens e mulheres com câncer de mama são pareados quanto à idade e ao estadiamento dos tumores, apresentam prognósticos similares.…”

Section: Prognósticounclassified

“…Uma série de casos de pacientes masculinos com câncer de mama demonstrou que cerca de 40% dos pacientes foram a óbito por outras causas que não o câncer de mama 4,13,14 . Os fatores mais importantes para o prognóstico são o estadiamento da doença no diagnóstico e o comprometimento axilar 8,26 . As taxas de sobrevida geral estimadas são de, aproximadamente, 40 a 65% em 5 anos e de 17 a 50% em 10 anos.…”

Section: Prognósticounclassified

See 1 more Smart Citation

Câncer de mama em homens

Nogueira¹,

Mendonça²,

Pasqualette³

2014

Rev. Bras. Mastol.

View full text Add to dashboard Cite

Keywords RESUMOO câncer de mama em homens é uma doença pouco conhecida. Sua abordagem em ensaios clínicos e publicações é pouco frequente. Foi realizada uma revisão da literatura, priorizando a epidemiologia, os fatores de risco, a patologia e os marcadores tumorais da doença. Corresponde a 1% de todas as neoplasias da mama. Os fatores de risco incluem hiperestrogenismo, idade, ascendência judaica, história familiar e síndrome de Klinefelter. Cerca de 90% dos tumores são ductais invasivos. De 80 a 90% dos casos apresentam receptores de estrógeno e progesterona positivos. O tratamento é semelhante ao do câncer de mama na mulher: cirurgia, hormonioterapia, quimioterapia e radioterapia são usadas, seguindo os guidelines femininos. Os fatores prognós-ticos incluem tamanho tumoral, grau histológico e comprometimento linfonodal. O câncer de mama é similar em homens e mulheres; todavia, os casos masculinos apresentam particularidades imuno-histoquímicas, mas não existem estudos suficientes para avaliar o impacto dessa característica no prognóstico e tratamento dessa neoplasia. ABSTRACT Breast cancer in men is a little known disease. His approach in clinical trials

show abstract

“…However, recent studies revealed that MBC and FBC patients have a similar prognosis (13 -15). One study showed that although overall survival (OS) was equivalent between both the sexes, diseasespecific survival was significantly better in MBC than in FBC (16). Thus, there is no consensus on the relationship between the patient's sex and prognosis in breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Poorer Survival of Male Breast Cancer Compared with Female Breast Cancer Patients May Be Due to Biological Differences

Chen¹,

Liu²,

Zhang³

et al. 2013

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Objective: The objective of the study was to compare disease-free survival and overall survival in a group of matched males and females with breast cancer, and to analyze possible treatment-and gender-related differences. Methods: We retrospectively analyzed the data of 150 operable male breast cancer patients treated in our hospital from December 1980 to June 2012. Each male breast cancer patient recorded in the database was matched with two female breast cancer patients of equal stage. Prognosis in terms of disease-free survival and overall survival was evaluated. Results: The mean age at diagnosis was 58.6 + 9.7 years for males and 57.2 + 10.3 years for females. The median follow-up was 69 months for males and 81 months for females. Significant differences were identified for tumor location, hormone receptor status, molecular subtypes and hormone therapy between the two groups. Monofactorial analysis demonstrated that tumor size, lymph node state, American Joint Committee on Cancer stage, molecular subtypes and adjuvant chemotherapy treatment were prognostic factors in male breast cancer patients. The 5-and 10-year disease-free survival rates were 65.6 and 40.1% for males, and 74.9 and 51.5% for females, respectively. The 5-and 10-year overall survival rates were 72.9 and 53.9% for males, and 83.2 and 68.5% for females, respectively. There was significantly difference in disease-free survival and overall survival between the two matched groups (P ¼ 0.002). Conclusions: Male breast cancer patients had inferior outcome despite of equal stage in comparison with matched female breast cancer patients, which demonstrates that biological differences may contribute to the worse prognosis.

show abstract

Men With Breast Cancer Have Better Disease-Specific Survival Than Women

Cited by 59 publications

References 26 publications

Male Breast Cancer: A Clinicopathologic Study of 42 Patients in Eastern India

Male Breast Cancer: A Clinicopathologic Study of 42 Patients in Eastern India

Câncer de mama em homens

Poorer Survival of Male Breast Cancer Compared with Female Breast Cancer Patients May Be Due to Biological Differences

Contact Info

Product

Resources

About